US20170121364A1 - Hydrophobic ceragenin compounds and devices incorporating same - Google Patents
Hydrophobic ceragenin compounds and devices incorporating same Download PDFInfo
- Publication number
- US20170121364A1 US20170121364A1 US15/406,667 US201715406667A US2017121364A1 US 20170121364 A1 US20170121364 A1 US 20170121364A1 US 201715406667 A US201715406667 A US 201715406667A US 2017121364 A1 US2017121364 A1 US 2017121364A1
- Authority
- US
- United States
- Prior art keywords
- csa
- hydrophobic
- compound
- polymer
- ceragenin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- DCOJJZCALNXQRN-PHGLHFJMSA-N [H][C@@]12C[C@H](OC(=O)CCN)CC[C@]1(C)[C@@]1([H])C[C@H](OC(=O)CCN)[C@]3(C)[C@@H]([C@H](C)CCC(=O)OCCCCCC)CC[C@@]3([H])[C@]1([H])[C@H](OC(=O)CCN)C2 Chemical compound [H][C@@]12C[C@H](OC(=O)CCN)CC[C@]1(C)[C@@]1([H])C[C@H](OC(=O)CCN)[C@]3(C)[C@@H]([C@H](C)CCC(=O)OCCCCCC)CC[C@@]3([H])[C@]1([H])[C@H](OC(=O)CCN)C2 DCOJJZCALNXQRN-PHGLHFJMSA-N 0.000 description 2
- 0 *.B.C.[1*]C1C([2*])C([3*])C([4*])C2([5*])C([6*])C([7*])C3([8*])C([10*])(C([11*])C([12*])C4([13*])C([18*])C([17*])C([16*])C([15*])C43[14*])C12[9*].[2HH] Chemical compound *.B.C.[1*]C1C([2*])C([3*])C([4*])C2([5*])C([6*])C([7*])C3([8*])C([10*])(C([11*])C([12*])C4([13*])C([18*])C([17*])C([16*])C([15*])C43[14*])C12[9*].[2HH] 0.000 description 1
- QPVYEWNKIRELOD-UHFFFAOYSA-N CN.CN.CN Chemical compound CN.CN.CN QPVYEWNKIRELOD-UHFFFAOYSA-N 0.000 description 1
- DDZOVTXQNYGRTC-HFNPYGFRSA-N [H][C@@]12C[C@H](OC(=O)CCN)CC[C@]1(C)[C@@]1([H])C[C@H](OC(=O)CCN)[C@]3(C)[C@@H]([C@H](C)CCC(=O)OCCCCCC)CC[C@@]3([H])[C@]1([H])[C@H](OC(=O)CCN)C2.[H][C@@]12C[C@H](OC(=O)CCN)CC[C@]1(C)[C@@]1([H])C[C@H](OC(=O)CCN)[C@]3(C)[C@@H]([C@H](C)CCC(=O)OCCCCCC)CC[C@@]3([H])[C@]1([H])[C@H](OC(=O)CCN)C2 Chemical compound [H][C@@]12C[C@H](OC(=O)CCN)CC[C@]1(C)[C@@]1([H])C[C@H](OC(=O)CCN)[C@]3(C)[C@@H]([C@H](C)CCC(=O)OCCCCCC)CC[C@@]3([H])[C@]1([H])[C@H](OC(=O)CCN)C2.[H][C@@]12C[C@H](OC(=O)CCN)CC[C@]1(C)[C@@]1([H])C[C@H](OC(=O)CCN)[C@]3(C)[C@@H]([C@H](C)CCC(=O)OCCCCCC)CC[C@@]3([H])[C@]1([H])[C@H](OC(=O)CCN)C2 DDZOVTXQNYGRTC-HFNPYGFRSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N45/00—Biocides, pest repellants or attractants, or plant growth regulators, containing compounds having three or more carbocyclic rings condensed among themselves, at least one ring not being a six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/145—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/145—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/208—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
Definitions
- the present invention relates to hydrophobic ceragenin compounds and devices incorporating the hydrophobic ceragenin compounds.
- the ceragenin compounds have hydrophobic substituents that give the compounds a relatively high CLogP value that allow the compounds to be non-covalently bonded to polymeric materials.
- Ceragenin compounds also referred to herein as cationic steroidal anti microbial compounds (CSA) are synthetically produced small molecule chemical compounds that include a sterol backbone having various charged groups (e.g., amine and cationic substituents) attached to the backbone.
- the backbone can be used to orient the amine or guanidine groups on one face, or plane, of the sterol backbone.
- Scheme I a scheme showing a compound having primary amino groups on one face, or plane, of a backbone is shown below in Scheme I:
- Ceragenins are cationic and amphiphilic, based upon the functional groups attached to the backbone. They are facially amphiphilic with a hydrophobic face and a polycationic face.
- the anti-microbial ceragenin compounds described herein act as anti-microbial agents (e.g., anti-bacterials, anti-fungals, and anti-virals). It is believed, for example, that the ant-microbial ceragenin compounds described herein act as anti-bacterials by binding to the outer cellular membrane of bacteria and other microbes and inserting into the cell membrane forming a pore that allows the leakage of ions that are critical to the microbe's survival and leading to the death of the affected microbe.
- the anti-microbial ceragenin compound described herein may also act to sensitize bacteria to other antibiotics.
- concentrations of the anti-microbial ceragenin compounds below the corresponding minimum bacteriostatic concentration the ceragenins cause bacteria to become more susceptible to other antibiotics by increasing the permeability of the outer membrane of the bacteria.
- the charged groups are responsible for disrupting the bacterial cellular membrane, and without the charged groups, the ceragenin compound cannot disrupt the membrane to cause cell death or sensitization.
- the present invention relates to ceragenin compounds that are relatively hydrophobic despite having a hydrophilic cationic face.
- the high hydrophobicity has been found to have a surprising and unexpected ability to bond with polymers and then selectively release from the polymeric materials to kill microbes.
- hydrophobic ceragenin compounds disclosed herein have (i) a sterol structure comprising four fused carbon rings; (ii) at least one cationic substituent attached to each of at least three of the four fused carbon rings so as to form an amphiphilic compound having a hydrophobic sterol face and a hydrophilic cationic face; (iii) at least one hydrophobic substituent attached to at least one of the fused carbon rings; and (iv) wherein the CSA compound has a CLogP value of at least 6.0.
- the CLogP value is achieved by selecting a proper hydrophobic substituent(s) in combination with proper cationic substituents.
- the cationic substituents and hydrophobic substituent(s) are selected to give a CLogP value of 6.0 or greater, 6.25 or greater, 6.5 or greater, 7.5 or greater, or even 10 or greater.
- greater hydrophobicity in the hydrophobic substituent is needed when cationic substituents with less hydrophobicity are used.
- the high CLogP value allows the compounds to be non-covalently bonded to polymers that have hydrophobic moieties.
- the hydrophobic compounds described herein can be non-covalently bonded to a hydrogel materials.
- the hydrophobic bonding allows for ceragenin compounds to associate with the polymer while having minimal impact on the ability to kill microbes.
- the hydrophobic ceragenin compound can selectively release from the polymer in the presence of microbes, thereby having a killing affect at lower concentration than one would predict and over an extended period of time. This is in contrast to studies done with covalently bonded ceragenins where immobilization impeded kill rates beyond the initial exposure.
- the ability of the hydrophobic ceragenin compounds to selectively release from a polymer to kill microbes is highly desirable and a surprising and unexpected result.
- ceragenins as used in the present invention surprisingly kill harmful microbes preferentially over normal flora, which means that the ceragenins can be used at lower concentrations compared to other antimicrobials while achieving the same or better effectiveness. This feature avoids many of the deleterious effects of prior art antimicrobials, many of which tend to kill the “good microbes.”
- the hydrophobic ceragenin compounds can be incorporated into or formed into medical devices such as medical devices to be implanted into a human or other animal.
- the hydrogels can be coated on a medical device or incorporated into a polymeric product such as an ophthalmic product.
- the medical devices incorporating the hydrophobic compounds can controllably release ceragenin compound in a concentration sufficient to meet regulatory requirements for maximum bacterial loads over weeks or even months.
- FIG. 1A illustrates example ceragenin compounds with a CLogP value less than 6.5
- FIG. 1B illustrates example ceragenin compounds with a CLogP value greater than 6.5
- FIG. 2 is a schematic representation of a substrate with a polymeric coating
- FIG. 3 is a graph showing elution of a ceragenin from a hydrogel in phosphate buffered saline
- FIG. 4 is a graph showing elution of a ceragenin from a hydrogel following autoclaving
- FIG. 5 is a graph showing elution of a ceragenin from a hydrogel in phosphate buffered saline and tryptic soy broth;
- FIG. 6 is a graph showing elution of a ceragenin from a hydrogel in buffer and 10 6 CFU of S. aureus ;
- FIG. 7 is a graph showing elution of a ceragenin from a hydrogel in buffer and 10 6 CFU of P. aeruginosa.
- hydrophobic ceragenin compounds disclosed herein have (i) a sterol structure comprising four fused carbon rings; (ii) at least one cationic substituent attached to each of at least three of the four fused carbon rings so as to form an amphiphilic compound having a hydrophobic sterol face and a hydrophilic cationic face; (iii) at least one hydrophobic substituent attached to at least one of the fused carbon rings; and (iv) wherein the CSA compound has a CLogP value of at least 6.0, at least 6.25, at least 6.5, at least 7.5, or at least 10.
- the CLogP value is achieved by selecting a proper hydrophobic substituent(s) in combination with proper cationic substituents.
- the cationic substituents and hydrophobic substituent(s) are selected to give a CLogP value of 6.0 or greater, 6.25 or greater, 6.5 or greater, 7.5 or greater, or even 10 or greater.
- the ceragenin compound may have a structure as shown in Formula I:
- FIG. 1B A number of examples of compounds of Formula I that may be used in the embodiments described herein are illustrated in FIG. 1B .
- Suitable examples of hydrophobic ceragenins useful in producing a composition that will selectively elute from a polymer include, but are not limited to, CSA-131, CSA-132, CSA-133, CSA-134, CSA-135, CSA-137, CSA-138, CSA-144, and CSA-145.
- the foregoing compounds have a CLogP value greater than 6.5, 7.5, 8.5, and in some cases greater than 10.
- CSA-135 was found to be less satisfactory compared to other ceragenins disclosed herein having different CLogP values relative to their ability to elute and kill microbes in a desired manner.
- CSA-136 was unexpectedly found to be advantageous over CSA-135 in its ability to elute and kill microbes. This suggests that desirable CLogP values between 6.0 and 9.0 may be desirable in some cases.
- FIG. 1A illustrates compounds that have a CLogP value less than 6.5.
- the compounds of FIG. 1A illustrate the types of changes that impart hydrophobicity of a CLogP value greater than 6.0, 6.25, 6.5, 7.5, 8.5, or 10.
- a hydrocarbon chain length of 9 or greater extending beyond the heteroatom is sufficient to impart the desired hydrophobicity.
- a hydrocarbon chain length of 11 carbon atoms or greater extending beyond the heteroatom is sufficient to impart a CLogP value greater than 6.5 (with the proviso that CSA-135 was unexpectedly found to be less satisfactory than CSA-136 in its ability to elute and kill microbes).
- Other moieties such as trimethyl silane can be added to allow for amine groups to be used with shorter chain lengths or to provide additional hydrophobicity.
- each of fused rings A, B, C, and D is independently saturated, or is fully or partially unsaturated, provided that at least two of A, B, C, and D are saturated, wherein rings A, B, C, and D form a ring system; each of m, n, p, and q is independently 0 or 1; each of R 1 through R 4 , R 5 , R 7 , R 11 , R 12 , R 15 , and R 16 is independently selected from the group consisting of hydrogen, hydroxyl, a substituted or unsubstituted (C 1 -C 10 )alkyl, (C 1 -C 10 )hydroxyalkyl, (C 1 -C 10 )alkyloxy-(C 1 -C 10 )alkyl, (C 1 -C 10 )alkylcarboxy-(C 1 -C 10 )alkyl, (C 1 -C 10 )alkylamino-(C 1 -C 10 )
- R 5 , R 8 , R 9 , R 10 , R 13 , and R 14 is independently deleted when one of fused rings A, B, C, or D is unsaturated so as to complete the valency of the carbon atom at that site, or selected from the group consisting of hydrogen, hydroxyl, a substituted or unsubstituted (C 1 -C 10 )alkyl, (C 1 -C 10 )hydroxyalkyl, (C 1 -C 10 )alkyloxy-(C 1 -C 10 )alkyl, a substituted or unsubstituted (C 1 -C 10 )aminoalkyl, a substituted or unsubstituted aryl, (C 1 -C 10 )haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, oxo, a linking group attached to a second steroid, a substituted or unsubsti
- R 1-4 , R 6 , R 7 , R 11 , R 12 , R 15 , R 15 , R 17 , and R 18 are independently selected from the group consisting of a substituted or unsubstituted (C 1 -C 10 )aminoalkyl, a substituted or unsubstituted (C 1 -C 10 )aminoalkyloxy, (C 1 -C 10 )alkylcarboxy-(C 1 -C 10 )alkyl, (C 1 -C 10 )alkylamino-(C 1 -C 10 )alkylamino, (C 1 -C 10 )alkylamino-(C 1 -C 10 )alkylamino (C 1 -C 10 )alkylamino, a substituted or unsubstituted (C 1 -C 10 )aminoalkylcarboxy, a substituted or unsubstituted (C 1 -C 10 )a
- a “ring” as used herein can be heterocyclic or carbocyclic.
- saturated used herein refers to the fused ring of Formula I having each atom in the fused ring either hydrogenated or substituted such that the valency of each atom is filled.
- unsaturated used herein refers to the fused ring of Formula I where the valency of each atom of the fused ring may not be filled with hydrogen or other substituents. For example, adjacent carbon atoms in the fused ring can be doubly bound to each other.
- Unsaturation can also include deleting at least one of the following pairs and completing the valency of the ring carbon atoms at these deleted positions with a double bond; such as R 5 and R 9 ; R 8 and R 10 ; and R 13 and R 14 .
- unsubstituted refers to a moiety having each atom hydrogenated such that the valency of each atom is filled.
- halo refers to a halogen atom such as fluorine, chlorine, bromine, or iodine.
- amino acid side chains include but are not limited to H (glycine), methyl (alanine), —CH 2 —(C ⁇ O)—NH 2 (asparagine), —CH 2 —SH (cysteine), and —CH(OH)—CH 3 (threonine).
- An alkyl group is a branched or unbranched hydrocarbon that may be substituted or unsubstituted.
- branched alkyl groups include isopropyl, sec-butyl, isobutyl, tert-butyl, sec-pentyl, isopentyl, tert-pentyl, isohexyl.
- Substituted alkyl groups may have one, two, three or more substituents, which may be the same or different, each replacing a hydrogen atom.
- Substituents are halogen (e.g., F, CI, Br, and I), hydroxyl, protected hydroxyl, amino, protected amino, carboxy, protected carboxy, cyan, methylsulfonylamino, alkoxy, acyloxy, nitro, and lower haloalkyl.
- halogen e.g., F, CI, Br, and I
- substituted refers to moieties having one, two, three or more substituents, which may be the same or different, each replacing a hydrogen atom.
- substituents include but are not limited to halogen (e.g., F, CI, Br, and I), hydroxyl, protected hydroxyl, amino, protected amino, carboxy, protected carboxy, cyan, methylsulfonylamino, alkoxy, alkyl, aryl, aralkyl, acyloxy, nitro, and lower haloalkyl.
- An aryl group is a C 6-20 aromatic ring, wherein the ring is made of carbon atoms (e.g., C 6 -C 14 , C 6-10 aryl groups).
- haloalkyl include fluoromethyl, dichloromethyl, trifluoromethyl, 1,1-difluoroethyl, and 2,2-dibromoethyl.
- An aralkyl group is a group containing 6-20 carbon atoms that has at least one aryl ring and at least one alkyl or alkylene chain connected to that ring.
- An example of an aralkyl group is a benzyl group.
- a linking group is any divalent moiety used to link one compound to another.
- a linking group may link a second compound to a compound of Formula I.
- An example of a linking group is (C 1 -C 10 )alkyloxy-(C 1 -C 10 )alkyl.
- Amino-protecting groups are known to those skilled in the art. In general, the species of protecting group is not critical, provided that it is stable to the conditions of any subsequent reaction(s) on other positions of the compound and can be removed at the appropriate point without adversely affecting the remainder of the molecule. In addition, a protecting group may be substituted for another after substantive synthetic transformations are complete. Clearly, where a compound differs from a compound disclosed herein only in that one or more protecting groups of the disclosed compound has been substituted with a different protecting group, that compound is within the disclosure. Further examples and conditions are found in T. W. Greene, Protective Groups in Organic Chemistry, (1st ed., 1981, 2nd ed., 1991).
- ceragenin compounds described herein preserve certain stereochemical and electronic characteristics found in steroids.
- the term “single face,” as used herein, refers to substituents on the fused sterol backbone having the same stereochemical orientation such that they project from one side of the molecule.
- substituents bound at R 3 , R 7 and R 12 of Formula I may be all ⁇ -substituted or ⁇ -substituted.
- the configuration of the moieties R 3 , R 7 and R 12 may be important for interaction with the cellular membrane.
- Compounds include but are not limited to compounds having cationic substituents (e.g., amine or guanidine groups) covalently attached to a sterol backbone or scaffold at any carbon position, e.g., cholic acid.
- a group is covalently attached at any one or more of positions R 3 , R 7 and R 12 of the sterol backbone.
- a group is absent from anyone, or more, of positions R 3 , R 7 and R 12 of the sterol backbone.
- ring systems can also be used, e.g., 5-member fused rings.
- Compounds with backbones having a combination of 5- and 6-membered rings are also contemplated.
- Cationic functional groups e.g., amine or guanidine groups
- Ceragenins with hydrophobic substituents can be prepared using the techniques described in Applicant's U.S. Pat. No. 6,767,904, with the modification being using longer chain alkyls to form a more hydrophobic substituent. For example, instead of using an octyl amine to form the functional group at R 17 , a corresponding longer chain amine can be used.
- Hydrophobic ceragenin compounds incorporated into a polymer can be non-covalently associated with the polymer. Upon contact with moisture, the ceragenin can leach or elute from the polymer. Ceragenins are generally soluble in water, and ceragenins can be associated with polymers to control release rates. Selection of appropriate polymer and ceragenin structures allows for an extended period of release of the ceragenin.
- the chain extending from a heteroatom (e.g., N) on R 17 can be tailored to allow varied rates of elution from a hydrogel polymer.
- Exemplary chains included, lipids, hydrophobic chains (e.g., aliphatic), hydrophilic (e.g., polyethyleneoxide), or any chain that interacts with the polymer is a way that allows modification of the rate of elution. Longer chain lengths will retain the ceragenin within the polymer matrix (in particular the hydrophobic domains).
- the ceragenin compound may have a carbon chain of at least 9 carbons attached to the D ring of the sterol group (Formula I).
- the carbon chain of at least 9 carbons may be attached to R 17 group of Formula I, or the C24 carbon or other similar carbon of a sterol backbone.
- ceragenins incorporated into the polymer may be soluble or partially soluble in aqueous solutions. Additionally, ceragenins when blended with the water and the appropriate surfactant can be handled in the form of gels, or emulsions.
- Block copolymers based on ethylene oxide and/or propylene oxide, in particular, Pluronic-type surfactants, are especially useful for this purpose. Pluronic is a product of BASF, a business with offices in Port Arthur, Texas, USA.
- Ceragenin compounds can be incorporated into a polymer at any suitable step during manufacture of a hydrogel material or product.
- a polymer can be brought into contact with a solution of ceragenins by immersion, spraying, printing, or coating, etc.
- Suitable solvents include short chain alcohols such as ethanol, methanol, isopropyl alcohol, and the like.
- the solvent used to incorporate the ceragenin can be removed, for example, by evaporation.
- the polymer can be dried by utilizing forced hot air, oven drying, air at room temperature, microwave drying, or the use of heated drying drums, vacuum chambers, etc. In some manufacturing systems the normal air flow and temperature sufficiently dry the substrate without a discrete drying process.
- Ceragenin compounds are known to be soluble in water.
- ceragenin compounds are also soluble in such materials as ethanol (and other alcohols), propylene glycol, glycerine, and polyols, or mixtures thereof with or without water can be used in incorporate ceragenin compounds into a polymeric material.
- ceragenins can be incorporated as gels, emulsions, suspensions, and in dry form.
- ceragenin is incorporated into a polymer during polymerization of the monomers.
- the ceragenin can be included in the monomer blend during polymerization.
- the ceragenin in final polymer can be noncovalently incorporated into the polymer and will accordingly elute when contacted with a solvent such as water.
- the hydrophobicity/hydrophilicity of the polymer and the ceragenin compound are selected to cause the ceragenin compound to non-covalently bond to the hydrogel polymer.
- the non-covalent bonding prevents the ceragenin compound from being released all at once in the presence of a solvent. Rather, the bonding allows the ceragenin compound to be released over time in the presence of a solvent.
- the non-covalent bonding depends on the composition of both the polymer and the ceragenin and therefore need to be selected together to produce the desired elution.
- the selection is typically carried out by selecting a particular polymer having desired chemical and mechanical properties for a particular application. For example, if the polymer is coated on a medical device to be implanted in vascular tissue, the polymer is selected for compatibility with vascular tissue and blood. If the polymer is used to form a contact lens, the polymer is selected for its compatibility with the eye and the need to form the polymer in a shape that will correct vision. The hydrophobicity/hydrophilicity of the polymer material is therefore somewhat constrained by the particular application.
- the ceragenin compound has a hydrophobicity selected to provide non-covalent bonding to the particular polymer.
- the ceragenin may be selected to have R groups that bond non-covalently the functional groups of the polymer.
- the solvent may also influence elution.
- the solvent is water.
- the solvent may be saline.
- the hydrogel polymer and the ceragenin compound are selected to yield non-covalent bonding that provides a release rate of 0.1-100 ⁇ g/ml, 0.5-50 ⁇ g/ml, or 1-10 ⁇ g/ml at three days, one week, or one month in water or saline.
- the foregoing elution rate remains within the foregoing ranges for at least 3 days, one week, or one month.
- hydrogel polymers One type of polymer that is particularly useful for incorporating hydrophobic ceragenin compounds are hydrogel polymers.
- hydrogel polymers examples include, but are not limited to, polyvinyl alcohol, sodium polyacrylate, acrylate polymers, polyethylene oxide, poly(2-acrylamido-2-methyl-1 -propanesulfonic acid) (polyAMP S), polyvinylpyrrolidone, polyacrylamide, silicone, agarose, methylcellulose, hyaluronan, hydrolyzed polyacrylicnitrile, combinations of these.
- the hydrogels may be copolymers.
- the copolymers may include hydrophobic and hydrophilic units.
- the hydrogel is suitable for manufacturing a contact lens.
- Hydrophilic contact lenses can be formed from cross-linked polymers based on hydrophilic derivatives of acrylic or methacrylic acid, hydrophilic vinylic monomers such as vinylpyrrolidone, and the like.
- the hydrogels preferably include hydrophobic regions made from blocks or monomers that are hydrophobic.
- the hydrogel polymers may be formed into a contact lens having a shape and structure suitable for correcting vision. Those skilled in the art are familiar with the shapes and structures of hydrogel polymers that can provide correction for vision. Other devices that can be formed from the hydrogels include wound healing devices such as tissue scaffolds and wound dressing.
- FIG. 2 is a schematic representation of a medical device 100 that includes a substrate 110 and a polymeric coating 120 .
- the substrate 110 may be made of any material suitable for supporting and/or adhering to a hydrogel material.
- the substrate can be polymeric, metallic, an alloy, inorganic, and/or organic.
- the substrate is a biocompatible or bioabsorbable material.
- biocompatible metallic materials include, but are not limited to, stainless steel, tantalum, titanium alloys (including nitinol), and cobalt alloys (including cobalt-chromium-nickel alloys).
- Suitable nonmetallic biocompatible materials include, but are not limited to, polyamides, polyolefins (i.e. polypropylene, polyethylene etc.), nonabsorbable polyesters (i.e.
- polyethylene terephthalate polyethylene terephthalate
- bioabsorbable aliphatic polyesters i.e. homopolymers and copolymers of lactic acid, glycolic acid, lactide, glycolide, para-dioxanone, trimethylene carbonate, s-caprolactone, and the like, and combinations of these
- the thickness of the substrate will depend on the device and the material but may be 0.1, 1.0, 10 mm or greater and/or 100, 10, or 1 mm or less and/or within a range thereof.
- the thickness of polymeric coating 120 is generally less than the thickness of substrate 110 .
- Polymeric coating 120 may have a thickness of 0.01, 0.1, 1.0, or 10 mm or greater and 100, 10, 1.0, or 0.1 mm or less or within a range thereof.
- the polymeric coating 120 can be continuous or non-continuous.
- the coating may be applied to the substrate using techniques such as dip coating, spin coating, or the like.
- Examples of medical devices that can be formed from a polymer containing hydrophobic ceragenin compounds or can have such a polymer coated thereon include but are not limited to bone implants, bone pins, bone screws, tissue grafts, airway devices such as endotracheal tubes, implantable devices such as coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, pacemaker and defibrillator leads, anastomotic clips, arterial closure devices, patent foramen ovale closure devices, and drug delivery balloons.
- the polymer may be coated on or form any portion of the structures of such devices and is preferably on an outer surface and more preferably on an out service that contacts tissue or a tissue air interface (when the device is implanted).
- a ceragenin compound can have hydrolysable linkages that attach the cationic substituents to the sterol group (e.g., ester bonds). Hydrolysis of these linkages inactivates the ceragenin.
- an acid can be added to achieve a pH less than 6, 5.5, 5, or 4.5 and optionally greater than 2, 2.5, or 3 or a range thereof. Stability before use is important to give a desired shelf life and instability during and after use can be desirable to prevent long term accumulation of ceragenins in biological systems.
- the degree of neutralization of the polymer may be adjusted during its manufacturing process, or subsequently.
- the ceragenin can be suspended or dissolved in an acidic solution; and when the ceragenin suspension or solution is added to the hydrogel polymer the degree of neutralization of the hydrogel would thereby be adjusted.
- CSA-138T2 radiolabeled version of CSA-138
- Lenses containing 1% CSA-138 were stored in 0.5 mL phosphate buffered saline (PBS) prior to testing. One set of lenses was autoclaved for 45 min before elution studies were performed. For elution studies, lenses were suspended in 2 ml aliquots of PBS, 10% TSB growth medium, 10% TSB growth medium containing 10 6 CFU of Staphylococcus aureus, or 10% TSB growth medium containing 10 6 CFU of Pseudomonas aeruginosa. Corresponding aliquots were exchanged every 24 h, including bacterial inocula. Samples were removed every 24 h and analyzed for the presence of CSA-138 using scintillation counting. A standard curve was generated to correlate counts per minute to concentration of CSA-138. All experiments were performed in triplicate.
- PBS phosphate buffered saline
- the MIC values of CSA-138 for S. aureus and for P. aeruginosa are 0.5 and 1.0 ⁇ g/ml, respectively.
- the elution of CSA-138 from lenses gives concentrations that are just able to eliminate the inocula introduced. Autoclaving the lenses, increasing the osmolality in the surrounding solution, and the presence of bacteria impact the elution profile modestly.
- CSA-138 Optimized the structure of CSA-138 has yielded a potent antimicrobial agent that associates with contact lens material and elutes at the concentration necessary to eliminate substantial inocula of Gram-positive and -negative bacteria. Considering the number of bacteria to which lenses are typically exposed, it is likely that lower concentrations of CSA-138 could be used while continuing to prevent bacterial growth on lenses.
- physiological conditions are aqueous conditions where the pH, temperature, and salt concentrations are generally suitable for sustaining life (e.g., for many, but not all devices, physiological conditions is often a pH near 7, temperatures near 37° C., and salt concentration near 150 mM).
Abstract
A hydrophobic cationic steroidal anti-microbial (ceragenin) compound forms an amphiphilic compound having a hydrophobic sterol face and a hydrophilic cationic face. Medical devices can be made incorporating the ceragenin compound.
Description
- This application is a continuation of U.S. patent application Ser. No. 14/602,499, filed Jan. 22, 2015, which is a continuation of U.S. patent application Ser. No. 13/554,957, filed Jul. 20, 2012, which claims the benefit of U.S. Prov. App. Nos. 61/572,714 filed Jul. 20, 2011, and 61/642,431, filed May 3, 2012, the disclosures of which are incorporated herein in their entirety.
- 1. The Field of the Invention
- The present invention relates to hydrophobic ceragenin compounds and devices incorporating the hydrophobic ceragenin compounds. The ceragenin compounds have hydrophobic substituents that give the compounds a relatively high CLogP value that allow the compounds to be non-covalently bonded to polymeric materials.
- 2. The Relevant Technology
- Ceragenin compounds, also referred to herein as cationic steroidal anti microbial compounds (CSA), are synthetically produced small molecule chemical compounds that include a sterol backbone having various charged groups (e.g., amine and cationic substituents) attached to the backbone. The backbone can be used to orient the amine or guanidine groups on one face, or plane, of the sterol backbone. For example, a scheme showing a compound having primary amino groups on one face, or plane, of a backbone is shown below in Scheme I:
- Ceragenins are cationic and amphiphilic, based upon the functional groups attached to the backbone. They are facially amphiphilic with a hydrophobic face and a polycationic face. Without wishing to be bound to any particular theory, the anti-microbial ceragenin compounds described herein act as anti-microbial agents (e.g., anti-bacterials, anti-fungals, and anti-virals). It is believed, for example, that the ant-microbial ceragenin compounds described herein act as anti-bacterials by binding to the outer cellular membrane of bacteria and other microbes and inserting into the cell membrane forming a pore that allows the leakage of ions that are critical to the microbe's survival and leading to the death of the affected microbe. In addition, the anti-microbial ceragenin compound described herein may also act to sensitize bacteria to other antibiotics. For example, at concentrations of the anti-microbial ceragenin compounds below the corresponding minimum bacteriostatic concentration, the ceragenins cause bacteria to become more susceptible to other antibiotics by increasing the permeability of the outer membrane of the bacteria.
- The charged groups are responsible for disrupting the bacterial cellular membrane, and without the charged groups, the ceragenin compound cannot disrupt the membrane to cause cell death or sensitization.
- The present invention relates to ceragenin compounds that are relatively hydrophobic despite having a hydrophilic cationic face. The high hydrophobicity has been found to have a surprising and unexpected ability to bond with polymers and then selectively release from the polymeric materials to kill microbes.
- In one embodiment, hydrophobic ceragenin compounds disclosed herein have (i) a sterol structure comprising four fused carbon rings; (ii) at least one cationic substituent attached to each of at least three of the four fused carbon rings so as to form an amphiphilic compound having a hydrophobic sterol face and a hydrophilic cationic face; (iii) at least one hydrophobic substituent attached to at least one of the fused carbon rings; and (iv) wherein the CSA compound has a CLogP value of at least 6.0.
- The CLogP value is achieved by selecting a proper hydrophobic substituent(s) in combination with proper cationic substituents. The cationic substituents and hydrophobic substituent(s) are selected to give a CLogP value of 6.0 or greater, 6.25 or greater, 6.5 or greater, 7.5 or greater, or even 10 or greater. In order to achieve the desired CLogP value, greater hydrophobicity in the hydrophobic substituent is needed when cationic substituents with less hydrophobicity are used.
- The high CLogP value allows the compounds to be non-covalently bonded to polymers that have hydrophobic moieties. For example, the hydrophobic compounds described herein can be non-covalently bonded to a hydrogel materials. The hydrophobic bonding allows for ceragenin compounds to associate with the polymer while having minimal impact on the ability to kill microbes.
- Surprisingly and unexpectedly, it has been found that by non-covalently bonding the ceragenin to a polymeric material using hydrophobic/hydrophilic interactions, the hydrophobic ceragenin compound can selectively release from the polymer in the presence of microbes, thereby having a killing affect at lower concentration than one would predict and over an extended period of time. This is in contrast to studies done with covalently bonded ceragenins where immobilization impeded kill rates beyond the initial exposure. The ability of the hydrophobic ceragenin compounds to selectively release from a polymer to kill microbes is highly desirable and a surprising and unexpected result.
- In addition, it has been found that the ceragenins as used in the present invention surprisingly kill harmful microbes preferentially over normal flora, which means that the ceragenins can be used at lower concentrations compared to other antimicrobials while achieving the same or better effectiveness. This feature avoids many of the deleterious effects of prior art antimicrobials, many of which tend to kill the “good microbes.”
- The hydrophobic ceragenin compounds can be incorporated into or formed into medical devices such as medical devices to be implanted into a human or other animal. For example, the hydrogels can be coated on a medical device or incorporated into a polymeric product such as an ophthalmic product. The medical devices incorporating the hydrophobic compounds can controllably release ceragenin compound in a concentration sufficient to meet regulatory requirements for maximum bacterial loads over weeks or even months.
- These and other features of the present invention will become more fully apparent from the following description and appended claims, or may be learned by the practice of the invention as set forth hereinafter.
- To further clarify the above and other advantages and features of the present invention, a more particular description of the invention will be rendered by reference to specific embodiments thereof which are illustrated in the appended drawings. It is appreciated that these drawings depict only illustrated embodiments of the invention and are therefore not to be considered limiting of its scope. The invention will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:
-
FIG. 1A illustrates example ceragenin compounds with a CLogP value less than 6.5; -
FIG. 1B illustrates example ceragenin compounds with a CLogP value greater than 6.5; -
FIG. 2 is a schematic representation of a substrate with a polymeric coating; -
FIG. 3 is a graph showing elution of a ceragenin from a hydrogel in phosphate buffered saline; -
FIG. 4 is a graph showing elution of a ceragenin from a hydrogel following autoclaving; -
FIG. 5 is a graph showing elution of a ceragenin from a hydrogel in phosphate buffered saline and tryptic soy broth; -
FIG. 6 is a graph showing elution of a ceragenin from a hydrogel in buffer and 106 CFU of S. aureus; and -
FIG. 7 is a graph showing elution of a ceragenin from a hydrogel in buffer and 106 CFU of P. aeruginosa. - In one embodiment, hydrophobic ceragenin compounds disclosed herein have (i) a sterol structure comprising four fused carbon rings; (ii) at least one cationic substituent attached to each of at least three of the four fused carbon rings so as to form an amphiphilic compound having a hydrophobic sterol face and a hydrophilic cationic face; (iii) at least one hydrophobic substituent attached to at least one of the fused carbon rings; and (iv) wherein the CSA compound has a CLogP value of at least 6.0, at least 6.25, at least 6.5, at least 7.5, or at least 10.
- The CLogP value is achieved by selecting a proper hydrophobic substituent(s) in combination with proper cationic substituents. The cationic substituents and hydrophobic substituent(s) are selected to give a CLogP value of 6.0 or greater, 6.25 or greater, 6.5 or greater, 7.5 or greater, or even 10 or greater.
- The ceragenin compound may have a structure as shown in Formula I:
-
- rings A, B, C, and D form a fused ring system and at least one of the R groups on 2 or 3 of the 4 four fused rings has a cationic substituent. The other R groups on FIG. I can have a variety of different functionalities, thus providing the ceragenin compound with the desired hydrophobic properties.
- In a preferred embodiment, p=1 and q=0 and at least R3, R7, and R12 independently include a cationic substituent attached to the fused ring system and R17 is a hydrophobic substituent that includes a hydrophobic group selected to give the ceragenin compound its desired hydrophobic/hydrophilic characteristics, which allows the ceragenin compound to non-covalently bond to a polymer and elute out over time and/or be selectively exposed to microbes. The R17 substituent may be hydrophobic but still include one or more heteroatoms (O or N) by having sufficient number of carbon atoms attached thereto to form a hydrophobic group. The hydrophobic group may be branched, substituted, or unsubstituted and the branching may occur at the heteroatom (e.g., dialkyl amines). The hydrophobic substituent is preferably attached at R17 when q=0 and R18 when q=1, but may be attached at other locations on the D ring or on R groups at locations on rings A, B, or C of Formula I. Where a hydrophobic substituent has a hydrophobic group attached to a heteroatom of an alkyl group, the hydrophobic group may have from 1-20 carbons, preferably 8, 9, 10, 11, 12, 13, 14, 15 or more carbons and 20, 18, 17, 16, 15 or fewer carbons or within a range thereof. The hydrophobic group may also include a hydrophobic moiety such as trimethylsilane. The hydrophobic group may include one or more alkyl groups each having 4 or more, 6 or more, 8 or more, 10 or more or 12 or more carbons. The hydrophobic group can be attached to the sterol structure by an alkyl group linking to the heteroatom. The linkage may be an ester, an ether, an amine, or an amide. Ester linkages are preferred where hydrolysis is desired and/or no charge is desired to impart greater hydrophobicity. There the heteroatom includes an amine, the hydrophobic group is preferably a dialkyl. Examples of a suitable hydrophobic substituents having a hydrophobic group as described herein are C13-alkylamino-C5-alkyl and di-(C1-C20)alkylamino-(C1-C10)-alkyl, which can be covalently bonded to the D ring at R17 or R18 (Formula I).
- A number of examples of compounds of Formula I that may be used in the embodiments described herein are illustrated in
FIG. 1B . Suitable examples of hydrophobic ceragenins useful in producing a composition that will selectively elute from a polymer include, but are not limited to, CSA-131, CSA-132, CSA-133, CSA-134, CSA-135, CSA-137, CSA-138, CSA-144, and CSA-145. The foregoing compounds have a CLogP value greater than 6.5, 7.5, 8.5, and in some cases greater than 10. Nevertheless, CSA-135 was found to be less satisfactory compared to other ceragenins disclosed herein having different CLogP values relative to their ability to elute and kill microbes in a desired manner. For example, CSA-136 was unexpectedly found to be advantageous over CSA-135 in its ability to elute and kill microbes. This suggests that desirable CLogP values between 6.0 and 9.0 may be desirable in some cases. -
FIG. 1A illustrates compounds that have a CLogP value less than 6.5. When contrasted with the compounds ofFIG. 1B , the compounds ofFIG. 1A illustrate the types of changes that impart hydrophobicity of a CLogP value greater than 6.0, 6.25, 6.5, 7.5, 8.5, or 10. For example, where the heteroatom is part of an ester group, a hydrocarbon chain length of 9 or greater extending beyond the heteroatom is sufficient to impart the desired hydrophobicity. Where an amine group is the heteroatom, a hydrocarbon chain length of 11 carbon atoms or greater extending beyond the heteroatom is sufficient to impart a CLogP value greater than 6.5 (with the proviso that CSA-135 was unexpectedly found to be less satisfactory than CSA-136 in its ability to elute and kill microbes). Other moieties such as trimethyl silane can be added to allow for amine groups to be used with shorter chain lengths or to provide additional hydrophobicity. - With reference again to Formula I, more specifically, each of fused rings A, B, C, and D is independently saturated, or is fully or partially unsaturated, provided that at least two of A, B, C, and D are saturated, wherein rings A, B, C, and D form a ring system; each of m, n, p, and q is independently 0 or 1; each of R1 through R4, R5, R7, R11, R12, R15, and R16 is independently selected from the group consisting of hydrogen, hydroxyl, a substituted or unsubstituted (C1-C10)alkyl, (C1-C10)hydroxyalkyl, (C1-C10)alkyloxy-(C1-C10)alkyl, (C1-C10)alkylcarboxy-(C1-C10)alkyl, (C1-C10)alkylamino-(C1-C10)alkyl, (C1-C10)alkylamino-(C1-C10)alkylamino, (C1-C10)alkylamino-(C1-C10)alkylamino-(C1-C10)alkylamino, a substituted or unsubstituted (C1-C10)aminoalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted arylamino-(C1-C10)alkyl, (C1-C10)haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, oxo, a linking group attached to a second steroid, a substituted or unsubstituted (C1-C10)aminoalkyloxy, a substituted or unsubstituted (C1-C10)aminoalkyloxy-(C1-C10)alkyl, a substituted or unsubstituted (C1-C10)aminoalkylcarboxy, a substituted or unsubstituted (C1-C10)aminoalkylaminocarbonyl, a substituted or unsubstituted (C1-C10)aminoalkylcarboxamido, H2N—HC(Q5)-C(O)—O—, H2N—HC(Q5)-C(O)—N(H)—, (C1-C10)azidoalkyloxy, (C1-C10)cyanoalkyloxy, P.G.-HN—HC(Q5)-C(O)—O—, (C1-C10)guanidinoalkyloxy, (C1-C10)quaternaryammoniumalkylcarboxy, and (C1-C10)guanidinoalkyl carboxy, where Q5 is a side chain of any amino acid (including a side chain of glycine, i.e., H), P.G. is an amino protecting group, and each of R5, R8, R9, R10, R13, and R14 is independently deleted when one of fused rings A, B, C, or D is unsaturated so as to complete the valency of the carbon atom at that site, or selected from the group consisting of hydrogen, hydroxyl, a substituted or unsubstituted (C1-C10)alkyl, (C1-C10)hydroxyalkyl, (C1-C10)alkyloxy-(C1-C10)alkyl, a substituted or unsubstituted (C1-C10)aminoalkyl, a substituted or unsubstituted aryl, (C1-C10)haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, oxo, a linking group attached to a second steroid, a substituted or unsubstituted (C1-C10)aminoalkyloxy, a substituted or unsubstituted (C1-C10)aminoalkylcarboxy, a substituted or unsubstituted (C1-C10)aminoalkylaminocarbonyl, H2N—HC(Q5)-C(O)—O—, H2N—HC(Q5)-C(O)—N(H)—, (C1-C10)azidoalkyloxy, (C1-C10)cyanoalkyloxy, P.G.-HN—HC(Q5)-C(O)—O—, (C1-C10)guanidinoalkyloxy, and (C1-C10)guanidinoalkylcarboxy, where Q5 is a side chain of any amino acid, PG. is an amino protecting group, provided that at least two or three of R1-4, R6, R7, R11, R12, R15, R15, R17, and R18 are independently selected from the group consisting of a substituted or unsubstituted (C1-C10)aminoalkyl, a substituted or unsubstituted (C1-C10)aminoalkyloxy, (C1-C10)alkylcarboxy-(C1-C10)alkyl, (C1-C10)alkylamino-(C1-C10)alkylamino, (C1-C10)alkylamino-(C1-C10)alkylamino (C1-C10)alkylamino, a substituted or unsubstituted (C1-C10)aminoalkylcarboxy, a substituted or unsubstituted arylamino (C1-C10)alkyl, a substituted or unsubstituted (C1-C10)aminoalkyloxy(C1-C10)aminoalkylaminocarbonyl, a substituted or unsubstituted (C1-C10)aminoalkylaminocarbonyl, a substituted or unsubstituted (C1-C10)aminoalkylcarboxyamido, a (C1-C10) quaternaryammonium alkylcarboxy, H2N—HC(Q5)-C(O)—O—, H2N—HC(Q5)-C(O)—N(H)—, (C1-C10)azidoalkyloxy, (C1-C10)cyanoalkyloxy, P.G.-HN—HC(Q5)-C(O)—O—, (C1-C10)guanidinoalkyloxy, and a (C1-C10)guanidinoalkylcarboxy; or a pharmaceutically acceptable salt thereof. Additional examples of specific CSA compounds are disclosed in Applicant's copending U.S. application Ser. No. 13/288,902 Filed Nov. 3, 2012, which is incorporated herein by reference.
- A “ring” as used herein can be heterocyclic or carbocyclic. The term “saturated” used herein refers to the fused ring of Formula I having each atom in the fused ring either hydrogenated or substituted such that the valency of each atom is filled. The term “unsaturated” used herein refers to the fused ring of Formula I where the valency of each atom of the fused ring may not be filled with hydrogen or other substituents. For example, adjacent carbon atoms in the fused ring can be doubly bound to each other. Unsaturation can also include deleting at least one of the following pairs and completing the valency of the ring carbon atoms at these deleted positions with a double bond; such as R5 and R9; R8 and R10; and R13 and R14.
- The term “unsubstituted” used herein refers to a moiety having each atom hydrogenated such that the valency of each atom is filled.
- The term “halo” used herein refers to a halogen atom such as fluorine, chlorine, bromine, or iodine.
- Examples of amino acid side chains include but are not limited to H (glycine), methyl (alanine), —CH2—(C═O)—NH2 (asparagine), —CH2—SH (cysteine), and —CH(OH)—CH3 (threonine).
- An alkyl group is a branched or unbranched hydrocarbon that may be substituted or unsubstituted. Examples of branched alkyl groups include isopropyl, sec-butyl, isobutyl, tert-butyl, sec-pentyl, isopentyl, tert-pentyl, isohexyl. Substituted alkyl groups may have one, two, three or more substituents, which may be the same or different, each replacing a hydrogen atom. Substituents are halogen (e.g., F, CI, Br, and I), hydroxyl, protected hydroxyl, amino, protected amino, carboxy, protected carboxy, cyan, methylsulfonylamino, alkoxy, acyloxy, nitro, and lower haloalkyl.
- The term “substituted” used herein refers to moieties having one, two, three or more substituents, which may be the same or different, each replacing a hydrogen atom. Examples of substituents include but are not limited to halogen (e.g., F, CI, Br, and I), hydroxyl, protected hydroxyl, amino, protected amino, carboxy, protected carboxy, cyan, methylsulfonylamino, alkoxy, alkyl, aryl, aralkyl, acyloxy, nitro, and lower haloalkyl.
- An aryl group is a C6-20 aromatic ring, wherein the ring is made of carbon atoms (e.g., C6-C14, C6-10 aryl groups). Examples of haloalkyl include fluoromethyl, dichloromethyl, trifluoromethyl, 1,1-difluoroethyl, and 2,2-dibromoethyl.
- An aralkyl group is a group containing 6-20 carbon atoms that has at least one aryl ring and at least one alkyl or alkylene chain connected to that ring. An example of an aralkyl group is a benzyl group.
- A linking group is any divalent moiety used to link one compound to another. For example, a linking group may link a second compound to a compound of Formula I. An example of a linking group is (C1-C10)alkyloxy-(C1-C10)alkyl.
- Amino-protecting groups are known to those skilled in the art. In general, the species of protecting group is not critical, provided that it is stable to the conditions of any subsequent reaction(s) on other positions of the compound and can be removed at the appropriate point without adversely affecting the remainder of the molecule. In addition, a protecting group may be substituted for another after substantive synthetic transformations are complete. Clearly, where a compound differs from a compound disclosed herein only in that one or more protecting groups of the disclosed compound has been substituted with a different protecting group, that compound is within the disclosure. Further examples and conditions are found in T. W. Greene, Protective Groups in Organic Chemistry, (1st ed., 1981, 2nd ed., 1991).
- A person of skill will recognize that various ceragenin compounds described herein preserve certain stereochemical and electronic characteristics found in steroids. The term “single face,” as used herein, refers to substituents on the fused sterol backbone having the same stereochemical orientation such that they project from one side of the molecule. For example, substituents bound at R3, R7 and R12 of Formula I may be all β-substituted or α-substituted. The configuration of the moieties R3, R7 and R12 may be important for interaction with the cellular membrane.
- Compounds include but are not limited to compounds having cationic substituents (e.g., amine or guanidine groups) covalently attached to a sterol backbone or scaffold at any carbon position, e.g., cholic acid. In various embodiments, a group is covalently attached at any one or more of positions R3, R7 and R12 of the sterol backbone. In additional embodiments, a group is absent from anyone, or more, of positions R3, R7 and R12 of the sterol backbone.
- Other ring systems can also be used, e.g., 5-member fused rings. Compounds with backbones having a combination of 5- and 6-membered rings are also contemplated. Cationic functional groups (e.g., amine or guanidine groups) can be separated from the backbone by at least one, two, three, four or more atoms.
- Ceragenins with hydrophobic substituents can be prepared using the techniques described in Applicant's U.S. Pat. No. 6,767,904, with the modification being using longer chain alkyls to form a more hydrophobic substituent. For example, instead of using an octyl amine to form the functional group at R17, a corresponding longer chain amine can be used.
- Hydrophobic ceragenin compounds incorporated into a polymer can be non-covalently associated with the polymer. Upon contact with moisture, the ceragenin can leach or elute from the polymer. Ceragenins are generally soluble in water, and ceragenins can be associated with polymers to control release rates. Selection of appropriate polymer and ceragenin structures allows for an extended period of release of the ceragenin.
- For example, the chain extending from a heteroatom (e.g., N) on R17 (Formula I) can be tailored to allow varied rates of elution from a hydrogel polymer. Exemplary chains included, lipids, hydrophobic chains (e.g., aliphatic), hydrophilic (e.g., polyethyleneoxide), or any chain that interacts with the polymer is a way that allows modification of the rate of elution. Longer chain lengths will retain the ceragenin within the polymer matrix (in particular the hydrophobic domains). In one embodiment, the ceragenin compound may have a carbon chain of at least 9 carbons attached to the D ring of the sterol group (Formula I). For example, the carbon chain of at least 9 carbons may be attached to R17 group of Formula I, or the C24 carbon or other similar carbon of a sterol backbone.
- The particular ceragenins incorporated into the polymer may be soluble or partially soluble in aqueous solutions. Additionally, ceragenins when blended with the water and the appropriate surfactant can be handled in the form of gels, or emulsions. Block copolymers based on ethylene oxide and/or propylene oxide, in particular, Pluronic-type surfactants, are especially useful for this purpose. Pluronic is a product of BASF, a business with offices in Port Arthur, Texas, USA.
- Ceragenin compounds can be incorporated into a polymer at any suitable step during manufacture of a hydrogel material or product. For example, in an embodiment, a polymer can be brought into contact with a solution of ceragenins by immersion, spraying, printing, or coating, etc. Suitable solvents include short chain alcohols such as ethanol, methanol, isopropyl alcohol, and the like. If desired, the solvent used to incorporate the ceragenin can be removed, for example, by evaporation. If necessary the polymer can be dried by utilizing forced hot air, oven drying, air at room temperature, microwave drying, or the use of heated drying drums, vacuum chambers, etc. In some manufacturing systems the normal air flow and temperature sufficiently dry the substrate without a discrete drying process.
- Ceragenin compounds are known to be soluble in water. Alternatively, ceragenin compounds are also soluble in such materials as ethanol (and other alcohols), propylene glycol, glycerine, and polyols, or mixtures thereof with or without water can be used in incorporate ceragenin compounds into a polymeric material. Furthermore ceragenins can be incorporated as gels, emulsions, suspensions, and in dry form.
- In another embodiment ceragenin is incorporated into a polymer during polymerization of the monomers. In these processes, the ceragenin can be included in the monomer blend during polymerization. The ceragenin in final polymer can be noncovalently incorporated into the polymer and will accordingly elute when contacted with a solvent such as water.
- When the ceragenin compound is incorporated into a polymeric material, the hydrophobicity/hydrophilicity of the polymer and the ceragenin compound are selected to cause the ceragenin compound to non-covalently bond to the hydrogel polymer. The non-covalent bonding prevents the ceragenin compound from being released all at once in the presence of a solvent. Rather, the bonding allows the ceragenin compound to be released over time in the presence of a solvent.
- The non-covalent bonding depends on the composition of both the polymer and the ceragenin and therefore need to be selected together to produce the desired elution. The selection is typically carried out by selecting a particular polymer having desired chemical and mechanical properties for a particular application. For example, if the polymer is coated on a medical device to be implanted in vascular tissue, the polymer is selected for compatibility with vascular tissue and blood. If the polymer is used to form a contact lens, the polymer is selected for its compatibility with the eye and the need to form the polymer in a shape that will correct vision. The hydrophobicity/hydrophilicity of the polymer material is therefore somewhat constrained by the particular application.
- The ceragenin compound has a hydrophobicity selected to provide non-covalent bonding to the particular polymer. The ceragenin may be selected to have R groups that bond non-covalently the functional groups of the polymer. For example, a polyacrylate based polymer may have a certain percentage of hydrophobic groups and hydrophilic groups in the polymer matrix and the ceragenin compound may be selected to have a hydrophobic R17 substituent (where q=0 in Formula I) that non-covalently bonds to the hydrophobic groups of the polymer to cause a relatively consistent elution over a period of days or weeks.
- In some cases, the solvent may also influence elution. In one embodiment, the solvent is water. In some embodiments, the solvent may be saline.
- In one embodiment, the hydrogel polymer and the ceragenin compound are selected to yield non-covalent bonding that provides a release rate of 0.1-100 μg/ml, 0.5-50 μg/ml, or 1-10 μg/ml at three days, one week, or one month in water or saline. In one embodiment, the foregoing elution rate remains within the foregoing ranges for at least 3 days, one week, or one month. These elution rates are achieved in part by the non-covalent bonding that prevents rapid release of the compound, which results in more compound being available at a later date.
- As mentioned above, it has been surprisingly found that non-covalently bound ceragenins in hydrogels selectively elute in the presence of microbes. This is a surprising and unexpected result that makes the use of polymer-ceragenin compounds particularly advantageous as compared to other materials, such as ceragenins covalently bonded to the surface of a polymer.
- Those skilled in the art will recognize that the selection of the particular polymer and ceragenin compound will depend on the particular application and the appropriate selection can be made by one of skill in the art using the teachings and examples provided herein.
- One type of polymer that is particularly useful for incorporating hydrophobic ceragenin compounds are hydrogel polymers.
- Examples of suitable hydrogel polymers include, but are not limited to, polyvinyl alcohol, sodium polyacrylate, acrylate polymers, polyethylene oxide, poly(2-acrylamido-2-methyl-1 -propanesulfonic acid) (polyAMP S), polyvinylpyrrolidone, polyacrylamide, silicone, agarose, methylcellulose, hyaluronan, hydrolyzed polyacrylicnitrile, combinations of these. The hydrogels may be copolymers. The copolymers may include hydrophobic and hydrophilic units.
- In one embodiment, the hydrogel is suitable for manufacturing a contact lens. Hydrophilic contact lenses can be formed from cross-linked polymers based on hydrophilic derivatives of acrylic or methacrylic acid, hydrophilic vinylic monomers such as vinylpyrrolidone, and the like. The hydrogels preferably include hydrophobic regions made from blocks or monomers that are hydrophobic.
- An example of a suitable contact lens hydrogel is disclosed in U.S. Pat. No. 8,011,784, which is incorporated herein by reference.
- The hydrogel polymers may be formed into a contact lens having a shape and structure suitable for correcting vision. Those skilled in the art are familiar with the shapes and structures of hydrogel polymers that can provide correction for vision. Other devices that can be formed from the hydrogels include wound healing devices such as tissue scaffolds and wound dressing.
- The polymers described herein may be used in various applications, including, but not limited to, medical devices, coatings, bandages, implants, tissue scaffolding, and the like.
FIG. 2 is a schematic representation of a medical device 100 that includes a substrate 110 and a polymeric coating 120. - The substrate 110 may be made of any material suitable for supporting and/or adhering to a hydrogel material. The substrate can be polymeric, metallic, an alloy, inorganic, and/or organic. In one embodiment, the substrate is a biocompatible or bioabsorbable material. Suitable biocompatible metallic materials include, but are not limited to, stainless steel, tantalum, titanium alloys (including nitinol), and cobalt alloys (including cobalt-chromium-nickel alloys). Suitable nonmetallic biocompatible materials include, but are not limited to, polyamides, polyolefins (i.e. polypropylene, polyethylene etc.), nonabsorbable polyesters (i.e. polyethylene terephthalate), and bioabsorbable aliphatic polyesters (i.e. homopolymers and copolymers of lactic acid, glycolic acid, lactide, glycolide, para-dioxanone, trimethylene carbonate, s-caprolactone, and the like, and combinations of these)
- The thickness of the substrate will depend on the device and the material but may be 0.1, 1.0, 10 mm or greater and/or 100, 10, or 1 mm or less and/or within a range thereof.
- The thickness of polymeric coating 120 is generally less than the thickness of substrate 110. Polymeric coating 120 may have a thickness of 0.01, 0.1, 1.0, or 10 mm or greater and 100, 10, 1.0, or 0.1 mm or less or within a range thereof.
- The polymeric coating 120 can be continuous or non-continuous. The coating may be applied to the substrate using techniques such as dip coating, spin coating, or the like.
- Examples of medical devices that can be formed from a polymer containing hydrophobic ceragenin compounds or can have such a polymer coated thereon include but are not limited to bone implants, bone pins, bone screws, tissue grafts, airway devices such as endotracheal tubes, implantable devices such as coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, pacemaker and defibrillator leads, anastomotic clips, arterial closure devices, patent foramen ovale closure devices, and drug delivery balloons. The polymer may be coated on or form any portion of the structures of such devices and is preferably on an outer surface and more preferably on an out service that contacts tissue or a tissue air interface (when the device is implanted).
- In one embodiment a ceragenin compound can have hydrolysable linkages that attach the cationic substituents to the sterol group (e.g., ester bonds). Hydrolysis of these linkages inactivates the ceragenin. To make the ceragenin stable, an acid can be added to achieve a pH less than 6, 5.5, 5, or 4.5 and optionally greater than 2, 2.5, or 3 or a range thereof. Stability before use is important to give a desired shelf life and instability during and after use can be desirable to prevent long term accumulation of ceragenins in biological systems.
- It may be advantageous to adjust the degree of neutralization of the polymer to improve the stability of the ceragenin. The degree of neutralization of the polymer can be adjusted during its manufacturing process, or subsequently. Alternatively, the ceragenin can be suspended or dissolved in an acidic solution; and when the ceragenin suspension or solution is added to the hydrogel polymer the degree of neutralization of the hydrogel would thereby be adjusted.
- To better understand the mechanism by which hydrophobic ceragenin compounds can prevent bacterial colonization, the bonding between CSA-138 and a hydrogel used in contact lenses was evaluated. In a first example, we determined the rate at which CSA-138 elutes from a hydrogel suitable for use in contact lenses. To quantify the amount of ceragenin eluting from the hydrogel, we used LC/MS using a mass-labeled internal standard. However, this method only gave detection limits of about 2 μg/ml, and we were able to effectively kill bacteria at constant elution rates below the detection limit. For example, the elution fell below detection limits within five days of elution from lenses in which CSA-138 had been incorporated at 1%, yet the ceragenins appeared to still be providing suitable kill rates.
- To decrease the detection limit for CSA-138, we prepared a radiolabeled version of CSA-138 (CSA-138T2), incorporated it into contact lenses, and quantified its elution from lenses using scintillation counting.
- Lenses containing 1% CSA-138 were stored in 0.5 mL phosphate buffered saline (PBS) prior to testing. One set of lenses was autoclaved for 45 min before elution studies were performed. For elution studies, lenses were suspended in 2 ml aliquots of PBS, 10% TSB growth medium, 10% TSB growth medium containing 106 CFU of Staphylococcus aureus, or 10% TSB growth medium containing 106 CFU of Pseudomonas aeruginosa. Corresponding aliquots were exchanged every 24 h, including bacterial inocula. Samples were removed every 24 h and analyzed for the presence of CSA-138 using scintillation counting. A standard curve was generated to correlate counts per minute to concentration of CSA-138. All experiments were performed in triplicate.
- Though some variations from day to day were observed, a recognizable trend was observed in the elution profile of lenses suspended in PBS (
FIG. 3 ). As expected, the elution on the first day was relatively high (about 2.2 μg/ml). Over the course of following 19 days, daily elution changed from approximately 1.6 to 1.4 μg/ml per day. - A comparable elution profile was observed with lenses that were autoclaved prior to the start of the study, except that the initial amount of material that eluted decreased somewhat (
FIG. 4 ). This decrease in elution is likely due to enhanced elution into the storage solution during the autoclaving process. Over the course of the study (fromday 2 to 20), the amount of CSA-138 that eluted changed from approximately 1.4 to 1.2 μg/ml per day. - It was anticipated that an increase in the osmolality of an aqueous solution would decrease the solubility of CSA-13 and slow elution. We determined the elution profile in 10% TSB in PBS, and as expected elution decreased (
FIG. 5 ) to match that seen with lenses that had been autoclaved. - Because kill rates appeared to be happening at such low concentrations, we hypothesized that the presence of bacteria was influencing the elution of CSA-138 from lenses. To test this hypothesis, lenses were incubated with S. aureus or P. aeruginosaand elution was monitored. These experiments were performed for nine and eight days, respectively. Elution of CSA-138 fluctuated substantially and to a much greater extent than outside of the presence of bacteria (
FIGS. 6 and 7 ). Because of these variations, the experiments were shortened relative to elution experiments without bacteria. Though there was substantial variation in the elution in the presence of bacteria, it was possible to determine the significance of the differences in elution comparing samples with and without bacteria. After the first day, differences gave a p value of 0.05 and for many of the days, the p value was below 0.01. These results argue that bacteria impact elution of CSA-138 from lenses. - The MIC values of CSA-138 for S. aureus and for P. aeruginosa are 0.5 and 1.0 μg/ml, respectively. The elution of CSA-138 from lenses gives concentrations that are just able to eliminate the inocula introduced. Autoclaving the lenses, increasing the osmolality in the surrounding solution, and the presence of bacteria impact the elution profile modestly.
- If one takes the elution profile given in
FIG. 5 and extends the trend until elution of CSA-138 drops below 1 μg/ml, this would require about 40 days (elution decreases from 1.4 to 1.2 μg/ml per day between days two and 20; a decrease from 1.2 to 1.0 μg/ml per day would be expected to require another 19 days). Thus, it would be expected that elution of CSA-138 would be sufficient to eliminate reasonable inocula of bacteria for as many as 40 days. As noted in a previous report, elution of CSA-138 from lenses prevents colonization by S. aureus for 30 consecutive days and by P. aeruginosa for 19 days. These studies are performed with relatively high inocula (106 CFU), and it is anticipated that CSA-138 eluting after 30 days would be sufficient to eliminate smaller inocula. - Optimization of the structure of CSA-138 has yielded a potent antimicrobial agent that associates with contact lens material and elutes at the concentration necessary to eliminate substantial inocula of Gram-positive and -negative bacteria. Considering the number of bacteria to which lenses are typically exposed, it is likely that lower concentrations of CSA-138 could be used while continuing to prevent bacterial growth on lenses.
- For purposes of this invention, “physiological conditions” are aqueous conditions where the pH, temperature, and salt concentrations are generally suitable for sustaining life (e.g., for many, but not all devices, physiological conditions is often a pH near 7, temperatures near 37° C., and salt concentration near 150 mM).
- The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.
Claims (13)
2. The CSA compound of claim 1 , wherein the CSA compound is a hydrochloride salt.
5. A device comprising a polymer structure and the CSA compound of claim 1 incorporated into the polymer structure.
6. The device of claim 5 , wherein the CSA compound is incorporated into the polymer structure with non-covalent interactions.
7. The device of claim 5 , wherein the polymer structure comprises polyvinyl alcohol, sodium polyacrylate, an acrylate polymer, polyethylene oxide, polyAMPS, polyvinylpyrrolidone, polyacrylamide, silicone, agarose, methylcellulose, hyaluronan, or a combination thereof.
8. The device of claim 5 , wherein the device comprises a medical device.
9. The device of claim 8 , wherein the medical device is selected from the group consisting of bone implant, bone pin, bone screw, tissue graft, endotracheal tube, coronary stent, peripheral stent, catheter, arterio-venous graft, by-pass graft, pacemaker or defibrillator lead, anastomotic clip, arterial closure device, patent foramen ovale closure device, and drug delivery balloon.
10. The device of claim 5 , wherein the polymer structure includes a polymer coated on a substrate.
11. The device of claim 5 , wherein the hydrophobic CSA compound elutes from the polymer structure in excess saline water at a rate of 0.1-100 μg/ml at 3 days and/or over a period of 3 days.
12. The device of claim 5 , wherein the hydrophobic CSA compound elutes from the polymer structure in excess saline water at a rate of 0.5-50 μg/ml at one week and/or over a period of one week.
13. The device of claim 5 , wherein the hydrophobic CSA compound elutes from the polymer structure in excess saline water at a rate of 1-10 μg/ml at one month and/or over a period of one month.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/406,667 US20170121364A1 (en) | 2011-07-20 | 2017-01-14 | Hydrophobic ceragenin compounds and devices incorporating same |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161572714P | 2011-07-20 | 2011-07-20 | |
US201261642431P | 2012-05-03 | 2012-05-03 | |
US13/554,957 US8975310B2 (en) | 2011-07-20 | 2012-07-20 | Hydrophobic ceragenin compounds and devices incorporating same |
US14/602,499 US9546195B2 (en) | 2011-07-20 | 2015-01-22 | Hydrophobic ceragenin compounds and devices incorporating same |
US15/406,667 US20170121364A1 (en) | 2011-07-20 | 2017-01-14 | Hydrophobic ceragenin compounds and devices incorporating same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/602,499 Continuation US9546195B2 (en) | 2011-07-20 | 2015-01-22 | Hydrophobic ceragenin compounds and devices incorporating same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170121364A1 true US20170121364A1 (en) | 2017-05-04 |
Family
ID=46584416
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/554,957 Active 2033-01-29 US8975310B2 (en) | 2011-07-20 | 2012-07-20 | Hydrophobic ceragenin compounds and devices incorporating same |
US13/554,930 Active 2033-06-25 US10676501B2 (en) | 2011-07-20 | 2012-07-20 | Hydrogel materials incorporating eluting ceragenin compound |
US14/602,499 Active US9546195B2 (en) | 2011-07-20 | 2015-01-22 | Hydrophobic ceragenin compounds and devices incorporating same |
US15/406,666 Abandoned US20170137459A1 (en) | 2011-07-20 | 2017-01-14 | Hydrophobic ceragenin compounds and devices incorporating same |
US15/406,667 Abandoned US20170121364A1 (en) | 2011-07-20 | 2017-01-14 | Hydrophobic ceragenin compounds and devices incorporating same |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/554,957 Active 2033-01-29 US8975310B2 (en) | 2011-07-20 | 2012-07-20 | Hydrophobic ceragenin compounds and devices incorporating same |
US13/554,930 Active 2033-06-25 US10676501B2 (en) | 2011-07-20 | 2012-07-20 | Hydrogel materials incorporating eluting ceragenin compound |
US14/602,499 Active US9546195B2 (en) | 2011-07-20 | 2015-01-22 | Hydrophobic ceragenin compounds and devices incorporating same |
US15/406,666 Abandoned US20170137459A1 (en) | 2011-07-20 | 2017-01-14 | Hydrophobic ceragenin compounds and devices incorporating same |
Country Status (12)
Country | Link |
---|---|
US (5) | US8975310B2 (en) |
EP (2) | EP2734246B1 (en) |
JP (1) | JP6272224B2 (en) |
KR (2) | KR20140063616A (en) |
CN (2) | CN104039369B (en) |
AU (2) | AU2012285818B2 (en) |
BR (1) | BR112014001444A2 (en) |
CA (2) | CA2842462C (en) |
ES (2) | ES2725784T3 (en) |
IL (1) | IL230520B (en) |
MX (1) | MX340644B (en) |
WO (2) | WO2013013223A1 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9943614B2 (en) | 2008-06-17 | 2018-04-17 | Brigham Young University | Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods |
AU2012285818B2 (en) | 2011-07-20 | 2015-07-02 | Brigham Young University | Hydrogel materials incorporating eluting ceragenin compound |
US8932614B2 (en) | 2011-08-25 | 2015-01-13 | Paul B. Savage | Incorporation of particulate ceragenins in polymers |
CN104080459B (en) | 2011-09-13 | 2018-07-03 | 布莱阿姆青年大学 | For treating the composition of bone disease and knochenbruch |
US9603859B2 (en) | 2011-09-13 | 2017-03-28 | Brigham Young University | Methods and products for increasing the rate of healing of tissue wounds |
US9694019B2 (en) | 2011-09-13 | 2017-07-04 | Brigham Young University | Compositions and methods for treating bone diseases and broken bones |
KR101966293B1 (en) | 2011-09-13 | 2019-04-08 | 브라이엄 영 유니버시티 | Products for healing of tissue wounds |
EP3449900A1 (en) | 2011-12-21 | 2019-03-06 | Brigham Young University | Oral care compositions |
US9533063B1 (en) | 2012-03-01 | 2017-01-03 | Brigham Young University | Aerosols incorporating ceragenin compounds and methods of use thereof |
EP3225113B1 (en) * | 2012-05-02 | 2020-09-02 | Brigham Young University | Methods for making ceragenin particulate materials |
BR112015008804A2 (en) | 2012-10-17 | 2017-07-04 | Univ Brigham Young | mastitis treatment and prevention |
JP6294352B2 (en) | 2013-01-07 | 2018-03-14 | ブリガム・ヤング・ユニバーシティBrigham Young University | Methods for reducing cell proliferation and treating certain diseases |
CN110420211A (en) | 2013-03-15 | 2019-11-08 | 布莱阿姆青年大学 | The method for treating inflammation, autoimmune disease and pain |
US10568893B2 (en) | 2013-03-15 | 2020-02-25 | Brigham Young University | Methods for treating inflammation, autoimmune disorders and pain |
US11524015B2 (en) | 2013-03-15 | 2022-12-13 | Brigham Young University | Methods for treating inflammation, autoimmune disorders and pain |
US9387215B2 (en) | 2013-04-22 | 2016-07-12 | Brigham Young University | Animal feed including cationic cholesterol additive and related methods |
WO2015048619A2 (en) * | 2013-09-30 | 2015-04-02 | Teleflex Medical Incorporated | Stabilized enzyme compositions |
US11690855B2 (en) | 2013-10-17 | 2023-07-04 | Brigham Young University | Methods for treating lung infections and inflammation |
US20150203527A1 (en) | 2014-01-23 | 2015-07-23 | Brigham Young University | Cationic steroidal antimicrobials |
CA2844321C (en) | 2014-02-27 | 2021-03-16 | Brigham Young University | Cationic steroidal antimicrobial compounds |
US9867836B2 (en) | 2014-03-13 | 2018-01-16 | Brigham Young University | Lavage and/or infusion using CSA compounds for increasing fertility in a mammal |
US10220045B2 (en) | 2014-03-13 | 2019-03-05 | Brigham Young University | Compositions and methods for forming stabilized compositions with reduced CSA agglomeration |
US9931350B2 (en) | 2014-03-14 | 2018-04-03 | Brigham Young University | Anti-infective and osteogenic compositions and methods of use |
US9686966B2 (en) | 2014-04-30 | 2017-06-27 | Brigham Young University | Methods and apparatus for cleaning or disinfecting a water delivery system |
US10441595B2 (en) | 2014-06-26 | 2019-10-15 | Brigham Young University | Methods for treating fungal infections |
US10238665B2 (en) | 2014-06-26 | 2019-03-26 | Brigham Young University | Methods for treating fungal infections |
US10227376B2 (en) | 2014-08-22 | 2019-03-12 | Brigham Young University | Radiolabeled cationic steroid antimicrobials and diagnostic methods |
US10155788B2 (en) | 2014-10-07 | 2018-12-18 | Brigham Young University | Cationic steroidal antimicrobial prodrug compositions and uses thereof |
WO2016115228A1 (en) * | 2015-01-13 | 2016-07-21 | Northeastern University | Electrostatic charge-induced coating of medical devices with biomolecules |
WO2016172553A1 (en) | 2015-04-22 | 2016-10-27 | Savage Paul B | Methods for the synthesis of ceragenins |
WO2016172543A1 (en) | 2015-04-22 | 2016-10-27 | Savage Paul B | Methods for the synthesis of ceragenins |
US9434759B1 (en) | 2015-05-18 | 2016-09-06 | Brigham Young University | Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds |
US20170080128A1 (en) * | 2015-09-21 | 2017-03-23 | Brigham Young University | Novel endotracheal tube for the reduction of intubation-related complication in neonates and babies |
US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
US20180272034A1 (en) * | 2017-03-21 | 2018-09-27 | Brigham Young University | Use of csa compounds to prevent microbial build-up or fouling of medical implants |
US10959433B2 (en) | 2017-03-21 | 2021-03-30 | Brigham Young University | Use of cationic steroidal antimicrobials for sporicidal activity |
WO2019173642A1 (en) * | 2018-03-07 | 2019-09-12 | Genberg Carl | Method of treating ciliated tissue using csa micelles |
US20200038559A1 (en) * | 2018-08-01 | 2020-02-06 | Boston Scientific Scimed, Inc. | Drug release coating compositions |
KR20200111525A (en) | 2019-03-19 | 2020-09-29 | 주식회사 엘지화학 | A battery module having an insulating pad having an extended length, a battery pack and a vehicle comprising the same |
US20210363174A1 (en) * | 2020-05-21 | 2021-11-25 | Brigham Young University | Cationic steroidal antimicrobial compounds with endogenous groups |
CN115322240B (en) * | 2022-08-17 | 2023-09-12 | 南宁师范大学 | Cholesterol selenocyanate compound, and preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040126409A1 (en) * | 2002-12-19 | 2004-07-01 | Mark Willcox | Biomedical devices with antimicrobial coatings |
US20050032765A1 (en) * | 1998-03-06 | 2005-02-10 | Brigham Young University, A Utah Corporation | Steroid derived antibiotics |
Family Cites Families (160)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1037074B (en) | 1957-03-25 | 1958-08-21 | Schering Ag | Oral care products |
US3843779A (en) | 1971-03-22 | 1974-10-22 | Colgate Palmolive Co | Process for preparing stable dentifrice |
US4248236A (en) | 1978-12-26 | 1981-02-03 | Linder Gerald S | Packaged medical appliance |
US4473988A (en) | 1979-10-24 | 1984-10-02 | Colgate-Palmolive Company | Dentifrice packaging process |
US4296206A (en) | 1980-04-30 | 1981-10-20 | United States Of America | Irreversible anti-glucocorticoids |
US4289755A (en) | 1980-11-03 | 1981-09-15 | Richardson-Vicks Inc. | Stable mouthwash compositions containing zinc and fluoride compounds |
FR2558107B3 (en) | 1984-01-12 | 1987-03-20 | Dechaume Geoffroy | SANDWICH MATERIAL WITH INTERNAL PAPER RIPPING AND EXTERIOR PROTECTION BY PLASTIC FILM AND METHODS OF MAKING SUCH MATERIAL |
US4661341A (en) | 1984-10-30 | 1987-04-28 | The Procter & Gamble Company | Oral compositions |
US4723950A (en) | 1984-12-12 | 1988-02-09 | C. R. Bard, Inc. | Urine drainage bag outlet with barrier against microbial infection |
US5380839A (en) | 1985-09-12 | 1995-01-10 | The Upjohn Company | Phenylpiperazinyl steroids |
US4842593A (en) | 1987-10-09 | 1989-06-27 | The Procter & Gamble Company | Disposable absorbent articles for incontinent individuals |
US4865855A (en) | 1988-01-11 | 1989-09-12 | Kimberly-Clark Corporation | Antimicrobial absorbent food pad |
US4990338A (en) | 1988-05-09 | 1991-02-05 | Dow Corning Corporation | Antimicrobial superabsorbent compositions and methods |
US5356630A (en) | 1989-02-22 | 1994-10-18 | Massachusetts Institute Of Technology | Delivery system for controlled release of bioactive factors |
US4972848A (en) | 1989-08-23 | 1990-11-27 | Medtronic, Inc. | Medical electrical lead with polymeric monolithic controlled release device and method of manufacture |
US5025754A (en) | 1990-02-01 | 1991-06-25 | David Plyler | Apparatus and method for providing drinking water to poultry |
GB9020075D0 (en) | 1990-09-14 | 1990-10-24 | Filler Aaron G | Contrast agents for magnetic resonance imaging of axonal transport |
US5310545A (en) | 1991-04-11 | 1994-05-10 | Drore Eisen | Method of treatment using mouthwashes containing steroids and antifungal agents and compositions of matter |
MX9204281A (en) | 1991-07-24 | 1993-04-01 | Smithkline Beecham Corp | ANTIBIOTIC FOOD COMPOSITIONS AND METHOD TO IMPROVE FOOD EFFICIENCY AND PROMOTE GROWTH IN MONOGASTRIC ANIMALS |
US5286479A (en) | 1991-12-10 | 1994-02-15 | The Dow Chemical Company | Oral compositions for suppressing mouth odors |
US5234703A (en) | 1992-10-31 | 1993-08-10 | Guthery B Eugene | Disinfecting product and process |
JP2877636B2 (en) | 1992-11-18 | 1999-03-31 | 積水化成品工業株式会社 | Antibacterial drip sheet |
US5352682A (en) | 1993-03-08 | 1994-10-04 | Digestive Care Inc. | Compositions containing salts of bile acid-aminosalicylate conjugates |
US5721359A (en) | 1993-03-12 | 1998-02-24 | Pharmacia & Upjohn Company | Crystalline ceftiofur free acid |
US5407573A (en) | 1993-06-01 | 1995-04-18 | Alpine Water Purification, Inc. | Continuous flow water-purifying device |
ATE210144T1 (en) | 1994-03-10 | 2001-12-15 | Magainin Pharma | USE OF STEROID DERIVATIVES AS MEDICINAL PRODUCTS |
US5856535A (en) | 1994-08-18 | 1999-01-05 | Magainin Pharmaceuticals, Inc. | Aminosterol ester compounds |
US5624704A (en) | 1995-04-24 | 1997-04-29 | Baylor College Of Medicine | Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent |
US5763430A (en) | 1995-06-07 | 1998-06-09 | Magainin Pharmaceuticals Inc. | Method of treating a viral infection by administering a steroid compound |
US5687714A (en) | 1995-10-10 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | Self-cleaning endotracheal tube apparatus |
JP3044367B2 (en) | 1995-11-13 | 2000-05-22 | 三洋化成工業株式会社 | Antimicrobial water-absorbing composition and method for producing the same |
US6132765A (en) * | 1996-04-12 | 2000-10-17 | Uroteq Inc. | Drug delivery via therapeutic hydrogels |
US5897770A (en) | 1997-10-23 | 1999-04-27 | Plymouth Products, Inc. | Center core cartridge feeder insert |
US20040170563A1 (en) | 1997-10-27 | 2004-09-02 | Meade Thomas J. | Magnetic resonance imaging agents for the delivery of therapeutic agents |
CN100398109C (en) | 1998-03-06 | 2008-07-02 | 杨伯翰大学 | Steroid derived antibiotics |
GB9804861D0 (en) | 1998-03-06 | 1998-04-29 | Res Inst Medicine Chem | Chemical compounds |
US6350738B1 (en) | 1998-03-06 | 2002-02-26 | Brigham Young University | Steroid derived antibiotics |
US6632457B1 (en) | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
US6329488B1 (en) | 1998-11-10 | 2001-12-11 | C. R. Bard, Inc. | Silane copolymer coatings |
US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
NO307168B1 (en) | 1999-03-01 | 2000-02-21 | Orix As | Oral preparation effective against halitosis |
US6217896B1 (en) * | 1999-04-01 | 2001-04-17 | Uab Research Foundation | Conjunctival inserts for topical delivery of medication or lubrication |
US6773717B1 (en) | 1999-07-09 | 2004-08-10 | Pennfield Oil Company | Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions |
US6673771B1 (en) | 1999-07-28 | 2004-01-06 | The Trustees Of The University Of Pennsylvania | Methods of inhibiting osteoclast activity |
EP1219631A4 (en) | 1999-08-23 | 2003-03-19 | Chugai Pharmaceutical Co Ltd | Antiandrogen agents |
US6737089B2 (en) | 1999-08-27 | 2004-05-18 | Morinda, Inc. | Morinda citrifolia (Noni) enhanced animal food product |
US6551608B2 (en) * | 2000-03-06 | 2003-04-22 | Porex Technologies Corporation | Porous plastic media with antiviral or antimicrobial properties and processes for making the same |
US6582713B2 (en) | 2000-04-06 | 2003-06-24 | Univ. Of Colorado - Colorado Springs | Compositions and methods for promoting wound healing |
EP1311531B1 (en) * | 2000-08-15 | 2016-05-11 | Brigham Young University | Steroid derived antibiotics |
JP3435405B2 (en) | 2000-11-24 | 2003-08-11 | 株式会社ティーセル研究所 | Livestock mastitis therapeutic agent and method for treating mastitis using the same |
US6514556B2 (en) | 2000-12-15 | 2003-02-04 | Ecolab Inc. | Method and composition for washing poultry during processing |
US6803066B2 (en) | 2001-01-18 | 2004-10-12 | Praxair Technology, Inc. | Sanitizing food products |
JP4674980B2 (en) | 2001-02-26 | 2011-04-20 | サンスター株式会社 | Alcohol-free liquid oral composition |
EP1372699A4 (en) | 2001-02-26 | 2006-05-24 | Univ Sydney | Method of improving the growth performance of an animal |
ES2189649B1 (en) | 2001-06-15 | 2004-09-16 | Oftrai S.L. | NEW DISINFECTANT AND ANTISEPTIC COMPOSITION. |
US6921390B2 (en) | 2001-07-23 | 2005-07-26 | Boston Scientific Scimed, Inc. | Long-term indwelling medical devices containing slow-releasing antimicrobial agents and having a surfactant surface |
WO2003015757A1 (en) | 2001-08-16 | 2003-02-27 | The Trustees Of The University Of Pennsylvania | Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
US9056048B2 (en) | 2001-08-16 | 2015-06-16 | The Trustees Of The University Of Pennsylvania | Synthesis and use of cationic steroids for anti-inflammatory drug therapy |
US6939376B2 (en) | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US6887270B2 (en) | 2002-02-08 | 2005-05-03 | Boston Scientific Scimed, Inc. | Implantable or insertable medical device resistant to microbial growth and biofilm formation |
US7048956B2 (en) | 2002-03-05 | 2006-05-23 | The Penn State Research Foundation | Process for antimicrobial treatment of fresh produce, particularly mushrooms |
DE10218147B4 (en) | 2002-04-23 | 2005-12-22 | Stockhausen Gmbh | Water-absorbing polymer particles retarding decomposition of body fluids, their preparation and use |
US8245708B2 (en) | 2002-05-07 | 2012-08-21 | The Research Foundation Of State University Of New York | Methods, devices and formulations for targeted endobronchial therapy |
US6689342B1 (en) | 2002-07-29 | 2004-02-10 | Warner-Lambert Company | Oral care compositions comprising tropolone compounds and essential oils and methods of using the same |
EP1542681A2 (en) | 2002-09-23 | 2005-06-22 | Schering Corporation | Use of posaconazole for the treatment of fungal infections |
US6966990B2 (en) | 2002-10-11 | 2005-11-22 | Ferro Corporation | Composite particles and method for preparing |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US7659061B2 (en) | 2002-11-19 | 2010-02-09 | Pharmacia & Upjohn Company | Pharmaceutical compositions having a modified vehicle |
US6928893B2 (en) | 2003-01-15 | 2005-08-16 | General Motors Corporation | Method of making a gas diffusion media and quality controls for same |
ES2270361T3 (en) | 2003-03-20 | 2007-04-01 | Pharmacia Corporation | DISPERSABLE FORMULATION OF AN ANTI-INFLAMMATOR AGENT. |
US6872306B2 (en) | 2003-04-22 | 2005-03-29 | Albert Shen | Multifunctional pure water maker |
DE10328261B4 (en) | 2003-06-23 | 2007-10-25 | Beiersdorf Ag | Disinfecting coating with silver coating and its use |
NZ543643A (en) | 2003-06-23 | 2007-09-28 | Beiersdorf Ag | Antimicrobial wound dressing with two layers and antimicrobial metal between layers but not on exterior |
US6872303B2 (en) | 2003-08-12 | 2005-03-29 | Ian M. Knapp | Water treatment cartridge |
GB0318901D0 (en) | 2003-08-12 | 2003-09-17 | Univ Bath | Improvements in or relating to bone substitute material |
US20050267051A1 (en) | 2003-12-19 | 2005-12-01 | Lee Henry J | Antineoplastic and anti-HIV conjugates of steroid acid and nucleosides |
US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
US20060062773A1 (en) | 2004-09-21 | 2006-03-23 | The Procter & Gamble Company | Compositions for maintaining and restoring normal gastrointestinal flora |
US20100092398A1 (en) | 2004-09-30 | 2010-04-15 | Max Reynolds | Antimicrobial compositions and applications therefore |
ES2545078T3 (en) | 2005-08-26 | 2015-09-08 | Becton Dickinson And Company | Sterilization methods of elastomeric sealing devices |
BRPI0615785B8 (en) | 2005-09-08 | 2021-05-25 | Yakult Honsha Kk | cholesterol absorption inhibitor composition comprising bacteria of the bifidobacterium genus |
JP2009510168A (en) | 2005-10-03 | 2009-03-12 | マーク エー. ピンスカイ | Compositions and methods for improved skin care |
US20100226884A1 (en) | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
US7842312B2 (en) | 2005-12-29 | 2010-11-30 | Cordis Corporation | Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same |
WO2007089907A2 (en) * | 2006-02-01 | 2007-08-09 | Brigham Young University | Cationic steroid antimicrobial compositions and methods of use |
WO2007089906A2 (en) | 2006-02-01 | 2007-08-09 | Brigham Young University | Cationic steroid antimicrobial compositions for treating or preventing herpes infections |
WO2007089903A2 (en) | 2006-02-01 | 2007-08-09 | Brigham Young University | Cationic steroid microbial compositions for treating or preventing influenza infections |
US7754705B2 (en) | 2006-02-01 | 2010-07-13 | Brigham Young University | Cationic steroid antimicrobial compositions and methods of use |
WO2007134176A2 (en) | 2006-05-10 | 2007-11-22 | Microban Products Company | Antimicrobial food pad |
US7858000B2 (en) * | 2006-06-08 | 2010-12-28 | Novartis Ag | Method of making silicone hydrogel contact lenses |
WO2007149868A2 (en) | 2006-06-20 | 2007-12-27 | The Regents Of The University Of California | Controlled release encapsulated anti-bacterial and anti-inflammatory nanoparticles |
US8685421B2 (en) * | 2006-07-07 | 2014-04-01 | Surmodics, Inc. | Beaded wound spacer device |
US20100022481A1 (en) * | 2006-08-02 | 2010-01-28 | Dong Wang | Drug Carriers, Their Synthesis, and Methods of Use Thereof |
WO2008038965A1 (en) | 2006-09-26 | 2008-04-03 | Kyungpook National University Industry-Academic Cooperation Foundation | 7alpha-aminosteroid derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and composition for anticancer or antibiotics containing the same as an active ingredient |
US9186511B2 (en) | 2006-10-13 | 2015-11-17 | Cyberonics, Inc. | Obstructive sleep apnea treatment devices, systems and methods |
US20080124376A1 (en) * | 2006-11-06 | 2008-05-29 | Novartis Ag | Ocular devices and methods of making and using thereof |
AU2008212673B2 (en) | 2007-02-07 | 2011-04-28 | Astrazeneca Ab | Napadisylate salt of a muscarinic M3 antagonist |
US7854941B2 (en) | 2007-02-12 | 2010-12-21 | The University Of Southern Mississippi | Method of attaching drug compounds to non-reactive polymer surfaces |
US9125807B2 (en) | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
US20090016973A1 (en) | 2007-07-09 | 2009-01-15 | Micropure, Inc. | Composition and Method for the Prevention of Oral Disease |
US8558051B2 (en) | 2007-07-18 | 2013-10-15 | The Procter & Gamble Company | Disposable absorbent article having odor control system |
US8772220B2 (en) | 2007-08-24 | 2014-07-08 | Sekisui Specialty Chemicals America, Llc | Chemical delivery product and process for making the same |
US20090068122A1 (en) | 2007-09-06 | 2009-03-12 | Shira Pilch | Dentifrice Compositions for Treating Xerostomia |
US9095568B2 (en) | 2007-09-26 | 2015-08-04 | Mark Berninger | Therapeutic and vaccine polyelectrolyte nanoparticle compositions |
US20090099531A1 (en) | 2007-10-15 | 2009-04-16 | Griesbach Iii Henry Louis | Packaging for selectivity lubricating part of a medical device |
AU2008314505C1 (en) | 2007-10-16 | 2020-11-05 | Progen Pg500 Series Pty Ltd | Novel sulfated oligosaccharide derivatives |
GB0724278D0 (en) | 2007-12-13 | 2008-01-30 | Syntopix Ltd | uses for antimicrobial agents |
KR101590201B1 (en) | 2008-01-14 | 2016-02-01 | 쿠퍼비젼 인터내셔날 홀딩 캄파니, 엘피 | Polymerizable contact lens formulations and contact lenses obtained therefrom |
WO2009144708A1 (en) | 2008-04-14 | 2009-12-03 | Ganot, Arie | Augmentation and treatment of gingival defects |
US9943614B2 (en) | 2008-06-17 | 2018-04-17 | Brigham Young University | Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods |
US20090324517A1 (en) | 2008-06-30 | 2009-12-31 | Dan Kline | Halitosis treatment |
ES2366890T3 (en) | 2008-07-07 | 2011-10-26 | Grc Pack Luxembourg S.A. | PACKAGING FOR FOOD PRODUCTS, AND A METHOD FOR PACKING A FOOD PRODUCT. |
EP2313101A4 (en) | 2008-07-09 | 2014-05-21 | Univ Nebraska | Functional micelles for hard tissue targeted delivery of chemicals |
US8247435B2 (en) | 2009-02-19 | 2012-08-21 | Thornthwaite Jerry T | Formulations for treating human and animal diseases |
US8623416B2 (en) | 2009-11-25 | 2014-01-07 | Michael Zasloff | Formulations comprising aminosterols |
US8529681B1 (en) | 2010-01-07 | 2013-09-10 | Sandia Corporation | Biofouling-resistant ceragenin-modified materials and structures for water treatment |
AU2011222612A1 (en) | 2010-03-04 | 2012-09-20 | The Trustees Of The University Of Pennsylvania Center For Technology Transfer | Antimicrobial cationic stereoids and methods of use |
JP5720103B2 (en) | 2010-03-18 | 2015-05-20 | 東レ株式会社 | Silicone hydrogels, ophthalmic lenses and contact lenses |
KR101134342B1 (en) | 2010-04-22 | 2012-04-09 | 주식회사 메가젠임플란트 | Dental implant fixture and implant set having the same |
US8871716B2 (en) | 2010-10-08 | 2014-10-28 | Korea Advanced Institute Of Science And Technology | Use of antimicrobial peptides in regeneration of skin cells |
US8691252B2 (en) | 2010-11-03 | 2014-04-08 | Brigham Young University | Storage-stable, anti-microbial compositions including ceragenin compounds and methods of use |
GB201021937D0 (en) | 2010-12-24 | 2011-02-02 | Reckitt & Colman Overseas | Skin sanitizer compositions comprising alcohol based emulsion |
CN102172356B (en) | 2011-03-03 | 2013-04-03 | 山东农业大学 | Use of taurochenodeoxycholic acid in prevention and treatment of osteoporosis |
US20130004586A1 (en) | 2011-06-24 | 2013-01-03 | Vachon David J | Biologically Efficacious Compositions, Articles of Manufacture and Processes for Producing and/or Using Same |
AU2012285818B2 (en) | 2011-07-20 | 2015-07-02 | Brigham Young University | Hydrogel materials incorporating eluting ceragenin compound |
WO2013029055A1 (en) | 2011-08-25 | 2013-02-28 | Brigham Young University | Incorporation of particulate ceragenins in polymers |
WO2013029059A1 (en) | 2011-08-25 | 2013-02-28 | Brigham Young University | Medical devices incorporating ceragenin-containing composites |
US8932614B2 (en) | 2011-08-25 | 2015-01-13 | Paul B. Savage | Incorporation of particulate ceragenins in polymers |
KR101966293B1 (en) | 2011-09-13 | 2019-04-08 | 브라이엄 영 유니버시티 | Products for healing of tissue wounds |
CN104080459B (en) | 2011-09-13 | 2018-07-03 | 布莱阿姆青年大学 | For treating the composition of bone disease and knochenbruch |
CA2855732C (en) | 2011-12-15 | 2016-06-28 | Colgate-Palmolive Company | Aqueous oral care compositions |
US20140363780A1 (en) | 2011-12-21 | 2014-12-11 | Brigham Young University | Oral care compositions |
EP3449900A1 (en) | 2011-12-21 | 2019-03-06 | Brigham Young University | Oral care compositions |
BR112014021505A2 (en) | 2012-03-01 | 2017-07-18 | Univ Brigham Young | antimicrobial food processing compositions including ceragenin compounds and methods of use |
US9533063B1 (en) * | 2012-03-01 | 2017-01-03 | Brigham Young University | Aerosols incorporating ceragenin compounds and methods of use thereof |
JP5803795B2 (en) | 2012-04-20 | 2015-11-04 | 富士通株式会社 | Receiver, frequency deviation calculation method, and computer program |
US20130280391A1 (en) * | 2012-04-24 | 2013-10-24 | Brigham Young University | Anti-microbial wash compositions including ceragenin compounds and methods of use for treating non-meat food products |
EP3225113B1 (en) | 2012-05-02 | 2020-09-02 | Brigham Young University | Methods for making ceragenin particulate materials |
JP2015520144A (en) | 2012-05-11 | 2015-07-16 | アクロン・モレキュールズ・アクチェンゲゼルシャフトAkron Molecules Ag | Use of compounds for the treatment of pain |
BR112015008804A2 (en) | 2012-10-17 | 2017-07-04 | Univ Brigham Young | mastitis treatment and prevention |
SI2900277T1 (en) | 2012-12-13 | 2022-05-31 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity |
JP6294352B2 (en) | 2013-01-07 | 2018-03-14 | ブリガム・ヤング・ユニバーシティBrigham Young University | Methods for reducing cell proliferation and treating certain diseases |
US11524015B2 (en) | 2013-03-15 | 2022-12-13 | Brigham Young University | Methods for treating inflammation, autoimmune disorders and pain |
CN110420211A (en) | 2013-03-15 | 2019-11-08 | 布莱阿姆青年大学 | The method for treating inflammation, autoimmune disease and pain |
US9387215B2 (en) | 2013-04-22 | 2016-07-12 | Brigham Young University | Animal feed including cationic cholesterol additive and related methods |
US11690855B2 (en) | 2013-10-17 | 2023-07-04 | Brigham Young University | Methods for treating lung infections and inflammation |
US20150203527A1 (en) | 2014-01-23 | 2015-07-23 | Brigham Young University | Cationic steroidal antimicrobials |
CA2844321C (en) | 2014-02-27 | 2021-03-16 | Brigham Young University | Cationic steroidal antimicrobial compounds |
US9867836B2 (en) | 2014-03-13 | 2018-01-16 | Brigham Young University | Lavage and/or infusion using CSA compounds for increasing fertility in a mammal |
US10220045B2 (en) | 2014-03-13 | 2019-03-05 | Brigham Young University | Compositions and methods for forming stabilized compositions with reduced CSA agglomeration |
US9931350B2 (en) | 2014-03-14 | 2018-04-03 | Brigham Young University | Anti-infective and osteogenic compositions and methods of use |
US10441595B2 (en) | 2014-06-26 | 2019-10-15 | Brigham Young University | Methods for treating fungal infections |
US10238665B2 (en) | 2014-06-26 | 2019-03-26 | Brigham Young University | Methods for treating fungal infections |
EP3191127A1 (en) * | 2014-09-13 | 2017-07-19 | Novartis AG | Combination therapies of egfr inhibitors |
WO2016172543A1 (en) | 2015-04-22 | 2016-10-27 | Savage Paul B | Methods for the synthesis of ceragenins |
CA2991726C (en) | 2015-04-22 | 2022-07-19 | Brigham Young University | Cationic steroidal antimicrobial salts |
WO2016172553A1 (en) | 2015-04-22 | 2016-10-27 | Savage Paul B | Methods for the synthesis of ceragenins |
US9434759B1 (en) | 2015-05-18 | 2016-09-06 | Brigham Young University | Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds |
US20170080128A1 (en) | 2015-09-21 | 2017-03-23 | Brigham Young University | Novel endotracheal tube for the reduction of intubation-related complication in neonates and babies |
US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
-
2012
- 2012-07-20 AU AU2012285818A patent/AU2012285818B2/en active Active
- 2012-07-20 BR BR112014001444A patent/BR112014001444A2/en not_active Application Discontinuation
- 2012-07-20 EP EP12740853.2A patent/EP2734246B1/en active Active
- 2012-07-20 ES ES12740853T patent/ES2725784T3/en active Active
- 2012-07-20 US US13/554,957 patent/US8975310B2/en active Active
- 2012-07-20 EP EP12740855.7A patent/EP2734247B1/en active Active
- 2012-07-20 WO PCT/US2012/047750 patent/WO2013013223A1/en active Application Filing
- 2012-07-20 JP JP2014521854A patent/JP6272224B2/en active Active
- 2012-07-20 CN CN201280045894.5A patent/CN104039369B/en active Active
- 2012-07-20 CA CA2842462A patent/CA2842462C/en active Active
- 2012-07-20 WO PCT/US2012/047746 patent/WO2013013221A1/en active Application Filing
- 2012-07-20 AU AU2012285816A patent/AU2012285816B2/en active Active
- 2012-07-20 ES ES12740855T patent/ES2728135T3/en active Active
- 2012-07-20 MX MX2014000787A patent/MX340644B/en active IP Right Grant
- 2012-07-20 KR KR1020147004478A patent/KR20140063616A/en active Application Filing
- 2012-07-20 US US13/554,930 patent/US10676501B2/en active Active
- 2012-07-20 KR KR1020197007349A patent/KR102220710B1/en active IP Right Grant
- 2012-07-20 CN CN201280045861.0A patent/CN104053458B/en active Active
- 2012-07-20 CA CA2842460A patent/CA2842460C/en active Active
-
2014
- 2014-01-19 IL IL230520A patent/IL230520B/en active IP Right Grant
-
2015
- 2015-01-22 US US14/602,499 patent/US9546195B2/en active Active
-
2017
- 2017-01-14 US US15/406,666 patent/US20170137459A1/en not_active Abandoned
- 2017-01-14 US US15/406,667 patent/US20170121364A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050032765A1 (en) * | 1998-03-06 | 2005-02-10 | Brigham Young University, A Utah Corporation | Steroid derived antibiotics |
US20040126409A1 (en) * | 2002-12-19 | 2004-07-01 | Mark Willcox | Biomedical devices with antimicrobial coatings |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9546195B2 (en) | Hydrophobic ceragenin compounds and devices incorporating same | |
US8932614B2 (en) | Incorporation of particulate ceragenins in polymers | |
US20140271761A1 (en) | Incorporation of particulate ceragenins in polymers | |
US20050124725A1 (en) | Triclosan and silver compound containing medical devices | |
WO2013029055A1 (en) | Incorporation of particulate ceragenins in polymers | |
CA3057863C (en) | Coating compositions, polymeric coatings, and methods | |
JP2019531843A (en) | Method for sterilizing a medical device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BRIGHAM YOUNG UNIVERSITY, UTAH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SAVAGE, PAUL B.;REEL/FRAME:040992/0804 Effective date: 20150121 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |